Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors-Reference-Cited by-同舟云学术

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Hammitt Laura L.¹,Quinn Dean²,Janczewska Ewa³,Pasquel Francisco J.⁴,Tytus Richard⁵,Reddy K. Rajender⁶,Abarca Katia⁷,Khaertynova Ilsiyar M.⁸,Dagan Ron⁹,Dawson Rachel¹⁰,McCauley Jennifer¹⁰,Shekar Tulin¹⁰,Fu Wei¹⁰,Pedley Alison¹⁰,Sterling Tina¹⁰,Tamms Gretchen¹⁰,Musey Luwy¹⁰,Buchwald Ulrike K.¹⁰

Affiliation:

1. International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

2. P3 Research, Wellington Clinical Trial Research Unit, Wellington, New Zealand

3. The School of Health Sciences in Bytom, Medical University of Silesia, Bytom, Poland

4. Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

5. Family Medicine, McMaster University, Ontario, Canada

6. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

7. Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile

8. Department of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia

9. The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel

10. Merck & Co., Inc., Rahway, NJ, USA

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2177066

Reference45 articles.

1. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence

2. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1

3. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23);Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices;MMWR,2010

4. Type 2 Diabetes and its Impact on the Immune System

5. Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children;Expert Review of Vaccines;2023-12-20

2. Pneumococcal Polysaccharide Conjugated Vaccines and the Problem of Changing Circulating Serotypes of Pneumococcus;Epidemiology and Vaccinal Prevention;2023-11-11

3. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age;Vaccine;2023-10

4. Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making;Vaccines;2023-04-27